|
|
 |
|
Viewing report
|
|
|
|
Commercial Insight: Antidyslipidemics - Branded Statins Beware, Generics Are Amongst You
Datamonitor, July 2006, Pages: 205
Commercial Insight: Antidyslipidemics explores current trends and key future issues in the management of dyslipidemia and the effects of generic competition and healthcare reforms on the main drug classes in this market.
The growth potential of the leading classes is discussed, and case studies are used to highlight possible strategies to maximize future growth for lipid management franchises.
Scope of this title:
- Event-driven sales forecasts, for the period 2006-15, for the US, Japan, France, Germany, Italy, Spain and the UK, along with a global overview
- Discussion of individual products in five main classes, focusing mainly on the statins, fibrates and other antidyslipidemics (e.g. Zetia, Niaspan)
- Profiles of the country and market specific issues which will impact future sales in the market including generic erosion and new product launches
- Commercial impact case studies on R&D innovation and the impact of generic erosion
Highlights of this title:
- 2006 is likely to mark an inflexion point in the sales value of the statin class across the seven major markets (7MM). Key drivers of this include patent expiries to Zocor and Pravachol in the US, with a predicted $8 billion expected to be wiped off the value of the branded statin monotherapy market between 2006-11 as a result.
- Strategies designed to blunt the impact of generic erosion on lipid management franchises include the development and commercialization of novel products. With further advances in LDL-C lowering efficacy unlikely, current research is focused on developing better tolerated and more effective HDL-C targeted therapies.
- A growing in-licensing and acquisition trend has surfaced in lipid management and antiatherosclerotic R&D. As in-house productivity falls, big pharma has spent billions on shoring up product pipelines, focusing particular on novel HDL-C targeted therapies, which we believe is evolving into the new battleground in lipid management.
Reasons to order your copy:
- Gain insight into the antidyslipidemics market via up-to-date thought-leader opinions and gold-standard IMS Health sales data
- Assess the potential impact of clinical trial results, generic erosion and new product launches on the antidyslipidemics market
- Access independent, event-driven forecasts for key antidyslipidemic products and classes across the seven major markets
Customers who bought this item also bought
Commercial Insight: Antidyslipidemics - The competitive cost-conscious antidyslipidemics market presents challenges
Strategic Perspectives: Antidyslipidemics - Current Market is not Conducive for Growth
Antidyslipidemics - Cholesterol Absorption of Lipitors Dominance
Statin Adjunct Therapy - Zetia, Revenue Protection for Zocor?
Commercial Insight: Antidyslipidemics - Statins Hit the Brakes on Market Growth
Antidyslipidemics - The Power Of Two
Pipeline Insight: Antidyslipidemics - The Power of Two
Zetia & Vytorin Case Study: Successfully Challenging The Statin Market
U.S. Lipid Therapeutics Market
Forecast Insight: Dyslipidemia - Genericization and Negative Trial Data Drive Market Shrinking
The Pharmaceutical Market Outlook to 2018: Key Threats and Opportunities for Big Pharma and its Responses to them
Lipid Regulators - Global Strategic Business Report
|
|
|
|
